Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary.
調査の概要
詳細な説明
OBJECTIVES:
Primary
- Evaluate the response rate in patients with previously untreated cancer of unknown primary treated with the combination of carboplatin, paclitaxel, and everolimus.
Secondary
- Assess time to progression, overall survival, duration of response, and time to treatment failure in patients treated with this regimen.
- Determine adverse events of this regimen in these patients.
- Perform descriptive correlative studies to determine response of specific tumor types, identified by the Origin-FFPE test, to this regimen.
OUTLINE: This is a multicenter study.
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive oral everolimus once daily on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients' tumor tissue samples from the most recent biopsy are analyzed for correlative studies, including gene expression profiling by Origin-FFPE test.
After completion of study therapy, patients are followed up every 3 months until disease progression, and then every 6 months for up to 3 years.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Colorado
-
Fort Collins、Colorado、アメリカ、80524
- Poudre Valley Hospital
-
Fort Collins、Colorado、アメリカ、80528
- Front Range Cancer Specialists
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Illinois
-
Moline、Illinois、アメリカ、61265
-
Moline、Illinois、アメリカ、61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
-
Indiana
-
Elkhart、Indiana、アメリカ、46515
- Elkhart General Hospital
-
Elkhart、Indiana、アメリカ、46514-2098
- Elkhart Clinic, LLC
-
Elkhart、Indiana、アメリカ、46514
- Michiana Hematology-Oncology, PC - Elkhart
-
Indianapolis、Indiana、アメリカ、46237
- St. Francis Hospital Cancer Care Services
-
Kokomo、Indiana、アメリカ、46904
- Howard Community Hospital
-
La Porte、Indiana、アメリカ、46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Mishawaka、Indiana、アメリカ、46545-1470
- Michiana Hematology-Oncology, PC - South Bend
-
Mishawaka、Indiana、アメリカ、46545-1470
- Saint Joseph Regional Medical Center
-
Plymouth、Indiana、アメリカ、46563
- Michiana Hematology Oncology PC - Plymouth
-
Richmond、Indiana、アメリカ、47374
- Reid Hospital & Health Care Services
-
South Bend、Indiana、アメリカ、46601
- Memorial Hospital of South Bend
-
South Bend、Indiana、アメリカ、46601
- CCOP - Northern Indiana CR Consortium
-
Westville、Indiana、アメリカ、46391
- Michiana Hematology Oncology PC - La Porte
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic, PC
-
Bettendorf、Iowa、アメリカ、52722
-
Cedar Rapids、Iowa、アメリカ、52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids、Iowa、アメリカ、52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive、Iowa、アメリカ、50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines、Iowa、アメリカ、50309
- CCOP - Iowa Oncology Research Association
-
Des Moines、Iowa、アメリカ、50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines、Iowa、アメリカ、50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines、Iowa、アメリカ、50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Ottumwa、Iowa、アメリカ、52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City、Iowa、アメリカ、51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City、Iowa、アメリカ、51102
- Mercy Medical Center - Sioux City
-
Sioux City、Iowa、アメリカ、51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute、Kansas、アメリカ、66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City、Kansas、アメリカ、67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado、Kansas、アメリカ、67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott、Kansas、アメリカ、66701
- Cancer Center of Kansas - Fort Scott
-
Independence、Kansas、アメリカ、67301
- Cancer Center of Kansas-Independence
-
Kingman、Kansas、アメリカ、67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence、Kansas、アメリカ、66044
- Lawrence Memorial Hospital
-
Liberal、Kansas、アメリカ、67901
- Cancer Center of Kansas, PA - Liberal
-
Newton、Kansas、アメリカ、67114
- Cancer Center of Kansas, PA - Newton
-
Parsons、Kansas、アメリカ、67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt、Kansas、アメリカ、67124
- Cancer Center of Kansas, PA - Pratt
-
Salina、Kansas、アメリカ、67401
- Cancer Center of Kansas, PA - Salina
-
Wellington、Kansas、アメリカ、67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita、Kansas、アメリカ、67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita、Kansas、アメリカ、67214
- CCOP - Wichita
-
Wichita、Kansas、アメリカ、67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita、Kansas、アメリカ、67208
- Associates in Womens Health, PA - North Review
-
Winfield、Kansas、アメリカ、67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Adrian、Michigan、アメリカ、49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor、Michigan、アメリカ、48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor、Michigan、アメリカ、48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek、Michigan、アメリカ、49017
- Battle Creek Health System Cancer Care Center
-
Dearborn、Michigan、アメリカ、48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba、Michigan、アメリカ、49431
- Green Bay Oncology, Limited - Escanaba
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Flint、Michigan、アメリカ、48503
- Genesys Hurley Cancer Institute
-
Grand Rapids、Michigan、アメリカ、49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids、Michigan、アメリカ、49503
- CCOP - Grand Rapids
-
Grand Rapids、Michigan、アメリカ、49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods、Michigan、アメリカ、48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain、Michigan、アメリカ、49801
- Dickinson County Healthcare System
-
Jackson、Michigan、アメリカ、49201
- Foote Memorial Hospital
-
Lansing、Michigan、アメリカ、48912-1811
- Sparrow Regional Cancer Center
-
Livonia、Michigan、アメリカ、48154
- St. Mary Mercy Hospital
-
Monroe、Michigan、アメリカ、48162
- Community Cancer Center of Monroe
-
Monroe、Michigan、アメリカ、48162
- Mercy Memorial Hospital - Monroe
-
Muskegon、Michigan、アメリカ、49444
- Mercy General Health Partners
-
Pontiac、Michigan、アメリカ、48341-2985
- St. Joseph Mercy Oakland
-
Port Huron、Michigan、アメリカ、48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Reed City、Michigan、アメリカ、49677
- Spectrum Health Reed City Hospital
-
Saginaw、Michigan、アメリカ、48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Saint Joseph、Michigan、アメリカ、49085
- Lakeside Cancer Specialists, PLLC
-
Saint Joseph、Michigan、アメリカ、49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City、Michigan、アメリカ、49684
- Munson Medical Center
-
Warren、Michigan、アメリカ、48093
- St. John Macomb Hospital
-
-
Minnesota
-
Bemidji、Minnesota、アメリカ、56601
- MeritCare Bemidji
-
Duluth、Minnesota、アメリカ、55805
- CCOP - Duluth
-
Duluth、Minnesota、アメリカ、55805
- Miller - Dwan Medical Center
-
Duluth、Minnesota、アメリカ、55805-1983
- Essentia Health - Duluth Clinic
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Springfield、Missouri、アメリカ、65804
- St. John's Regional Health Center
-
Springfield、Missouri、アメリカ、65807
- Hulston Cancer Center at Cox Medical Center South
-
Springfield、Missouri、アメリカ、65804
- CCOP - Cancer Research for the Ozarks
-
-
Montana
-
Billings、Montana、アメリカ、59101
- CCOP - Montana Cancer Consortium
-
Billings、Montana、アメリカ、59101
- St. Vincent Healthcare Cancer Care Services
-
Billings、Montana、アメリカ、59107-7000
- Billings Clinic - Downtown
-
Billings、Montana、アメリカ、59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman、Montana、アメリカ、59715
- Bozeman Deaconess Cancer Center
-
Butte、Montana、アメリカ、59701
- St. James Healthcare Cancer Care
-
Great Falls、Montana、アメリカ、59405
- Sletten Cancer Institute at Benefis Healthcare
-
Helena、Montana、アメリカ、59601
- St. Peter's Hospital
-
Kalispell、Montana、アメリカ、59901
- Kalispell Regional Medical Center
-
Missoula、Montana、アメリカ、59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula、Montana、アメリカ、59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck、North Dakota、アメリカ、58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck、North Dakota、アメリカ、58501
- Mid Dakota Clinic, PC
-
Bismarck、North Dakota、アメリカ、58502
- St. Alexius Medical Center Cancer Center
-
Fargo、North Dakota、アメリカ、58122
- CCOP - MeritCare Hospital
-
Fargo、North Dakota、アメリカ、58102
- MeritCare Broadway
-
-
Ohio
-
Bowling Green、Ohio、アメリカ、43402
- Wood County Oncology Center
-
Dayton、Ohio、アメリカ、45405
- Grandview Hospital
-
Dayton、Ohio、アメリカ、45406
- Good Samaritan Hospital
-
Dayton、Ohio、アメリカ、45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton、Ohio、アメリカ、45415
- Samaritan North Cancer Care Center
-
Dayton、Ohio、アメリカ、45420
- CCOP - Dayton
-
Elyria、Ohio、アメリカ、44035
- Community Cancer Center
-
Elyria、Ohio、アメリカ、44035
- Hematology Oncology Center
-
Findlay、Ohio、アメリカ、45840
- Blanchard Valley Medical Associates
-
Franklin、Ohio、アメリカ、45005-1066
- Middletown Regional Hospital
-
Greenville、Ohio、アメリカ、45331
- Wayne Hospital
-
Kettering、Ohio、アメリカ、45429
- Charles F. Kettering Memorial Hospital
-
Lima、Ohio、アメリカ、45804
- Lima Memorial Hospital
-
Maumee、Ohio、アメリカ、43537-1839
- Northwest Ohio Oncology Center
-
Oregon、Ohio、アメリカ、43616
- St. Charles Mercy Hospital
-
Oregon、Ohio、アメリカ、43616
- Toledo Clinic - Oregon
-
Sylvania、Ohio、アメリカ、43560
- Flower Hospital Cancer Center
-
Tiffin、Ohio、アメリカ、44883
- Mercy Hospital of Tiffin
-
Toledo、Ohio、アメリカ、43608
- St. Vincent Mercy Medical Center
-
Toledo、Ohio、アメリカ、43606
- Toledo Hospital
-
Toledo、Ohio、アメリカ、43614
- Medical University of Ohio Cancer Center
-
Toledo、Ohio、アメリカ、43617
- CCOP - Toledo Community Hospital
-
Toledo、Ohio、アメリカ、43623
- Toledo Clinic, Incorporated - Main Clinic
-
Toledo、Ohio、アメリカ、43623
- St. Anne Mercy Hospital
-
Troy、Ohio、アメリカ、45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wauseon、Ohio、アメリカ、43567
- Fulton County Health Center
-
Xenia、Ohio、アメリカ、45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg、Virginia、アメリカ、22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay、Wisconsin、アメリカ、54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay、Wisconsin、アメリカ、54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay、Wisconsin、アメリカ、54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc、Wisconsin、アメリカ、54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette、Wisconsin、アメリカ、54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls、Wisconsin、アメリカ、54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan、Wisconsin、アメリカ、53081
- St. Nicholas Hospital
-
Sturgeon Bay、Wisconsin、アメリカ、54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Histological confirmation of metastatic adenocarcinoma, poorly differentiated non-small cell carcinoma, or poorly differentiated squamous carcinoma
- Adequate FFPE tissue or re-biopsy planned after registration but prior to treatment
- Measurable disease as defined; for patients having only lesions measuring at least 1 cm to =< 2 cm must use spiral computed tomography (CT) imaging for both pre- and post-treatment tumor assessments; disease that has received prior radiation (performed for palliative reasons) cannot be used for measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Hemoglobin (Hgb) >= 9.0 g/dL
- Absolute neutrophil count (ANC) >= 1,500/uL
- Platelet count >= 100,000/uL
- Total bilirubin =< upper limits of normal (ULN); if liver metastases are present, total bilirubin =< 2 x ULN
- Aspartate aminotransferase (AST) =< 2.5 x ULN; if liver metastases are present, AST =< 5 x ULN
- Creatinine =< 1.25 x ULN; if > 1.25 x ULN calculated creatinine clearance must be >= 60 ml/min
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Provide informed written consent
- Willingness to return to NCCTG enrolling institution for follow-up
- Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Exclusion Criteria
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception; note: adequate contraception must be used throughout the trial and for 8 weeks after the last dose of RAD001, by both sexes
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
History of any of the following:
- Known to be human immunodeficiency virus (HIV) positive
- Known prior/current history of hepatitis related to hepatitis B or hepatitis C
Uncontrolled intercurrent illness including, but not limited to the following:
- Ongoing or active infection (acute or chronic)
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Severely impaired lung function
- Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN (note: optimal glycemic control should be achieved before starting trial therapy)
- Liver disease such as cirrhosis or severe hepatic impairment
- Psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< 4 weeks prior to registration
- Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
- Untreated brain metastases; NOTE: patients with treated, stable brain metastases for at least 12 weeks prior to study entry are eligible for enrollment
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- Active, bleeding diathesis
- Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
- Currently on enzyme inducing anti-convulsants (EIACs) or other strong inducers or strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
- Current use of warfarin (Coumadin); EXCEPTION: current use of low-molecular weight heparin is allowed
- Known to be HIV positive
- Inoculated with live attenuated vaccines =< 2 weeks prior to registration; note: close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines
- =< 4 weeks from major surgery; note: for this study, diagnostic laparoscopy (without other intervention) and/or biopsies (needle aspirate, core biopsy, open biopsy, etc.) are not considered major surgery
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (carboplatin, paclitaxel, and everolimus)
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1.
Patients also receive everolimus PO QD on days 1, 8, and 15.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
与えられた IV
与えられた IV
与えられたPO
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Confirmed Tumor Responses
時間枠:First 6 Cycles of treatment (an average of 6 months)
|
Confirmed tumor response was defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:
|
First 6 Cycles of treatment (an average of 6 months)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival
時間枠:Time from registration to death or last follow-up (up to 3 years)
|
Overall survival was defined as the time from study enrollment to the time of death from any cause or last follow-up.
|
Time from registration to death or last follow-up (up to 3 years)
|
|
Progression-free Survival
時間枠:Time from registration to the disease progression or death (up to 3 years)
|
The progression-free survival (PFS) was defined as the time from date of registration to the documentation of disease progression or death as a result of any cause, whichever comes first.
|
Time from registration to the disease progression or death (up to 3 years)
|
|
Duration of Response
時間枠:Up to 3 years
|
Duration of response was defined for all evaluable participants who have achieved an objective response as the date at which the participant's objective status is first noted to be either CR or PR to the date progression is documented.
|
Up to 3 years
|
|
Time to Treatment Failure
時間枠:Up to 3 years
|
Time to treatment failure was defined to be the time from the date of registration to the date at which the participant is removed from treatment due to progression, adverse events, or refusal.
|
Up to 3 years
|
協力者と研究者
捜査官
- スタディチェア:Matthew P. Goetz, MD、Mayo Clinic
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- NCCTG-N0871
- NCI-2011-01926 (レジストリ識別子:CTRP (Clinical Trials Reporting System))
- CDR0000643361 (レジストリ識別子:PDQ (Physician Data Query))
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
パクリタキセルの臨床試験
-
Sun Yat-sen Universityまだ募集していません胃食道接合部腺癌 | 進行胃がん | ラムシルマブ | フルキンチニブ
-
BioNTech SEBristol-Myers Squibb募集乳房腫瘍アメリカ, オーストラリア, 中国, 日本, イタリア, スペイン, イギリス, ベルギー, ポーランド, グルジア, 韓国, チェコ, ドイツ
-
Zhijie WangPeking University Cancer Hospital & Institute; Hebei Medical University Fourth Hospitalまだ募集していません局所進行または転移性非小細胞肺がん | SMARCA4欠損腫瘍中国
-
The First Affiliated Hospital of Zhengzhou University招待による登録
-
Cancer Institute and Hospital, Chinese Academy...募集
-
Ajou University School of Medicine積極的、募集していない